Publishers Alliance

Cancer Management and Research

The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer

[Cancer Management and Research] FDA approval of ramucirumab has improved overall survival for patients with advanced gastric carcinoma; however, most patients do not achieve a cure, heightening awareness of health-related quality of life. This report focused on HRQoL and the impact of ramucirumab on HRQoL, as well as summarized studies evaluating the benefits of systemic therapies on HRQoL in patients with advanced gastric cancer.

Blood and Lymphatic Cancer: Targets and Therapy

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma

[Blood and Lymphatic Cancer: Targets and Therapy] First approved in 2011, the CD30 directed antibody-drug conjugate brentuximab vedotin is used in previously untreated and R/R classical Hodgkin lymphoma (cHL). In this review, researchers discuss the expanded indications for BV in cHL to include maintenance therapy after ASCT and in combination with chemotherapy and immunotherapy.

Next post in Publishers Alliance